Nextmune Strengthens Portfolio and Commitment to Veterinary Dermatology with Acquisition of VetBiotek

December 23, 2023 05:50 AM AEDT | By EIN Presswire

Google News:

Recent News

Fortune Minerals Announces Results of Annual Meeting of Shareholders

Meet Megan McKray: A Champion for Working Parents and Caregivers

SLB OneSubsea Secures EPC Contract for Northern Lights CO2 Transport a...

Wunderkind Launches "Build": A Flexible, Developer-Ready Framework for...

PHOENIX, ARIZONA, UNITED STATES, December 22, 2023 /EINPresswire.com/ -- Nextmune, a leading global specialty pharma company dedicated to enhancing the health and well-being of companion animals, proudly announces its acquisition of VetBiotek, a pioneering force in innovative solutions for veterinary health. This strategic move underscores Nextmune's commitment to advancing dermatological care for pets and reinforces its position as a key player in the industry.

Founded in October 2014 by Tom Bell, VetBiotek swiftly gained recognition for its cutting-edge MicroSilver BG™️ formulations tailored to combat biofilm and bacterial growth. These formulations not only support antibiotic stewardship, but also alleviate antibiotic resistance. With a focus on skin health, VetBiotek's products utilize Ceramide III to restore the lipid barrier gently, ensuring the well-being of pets.

"VetBiotek is confident that joining the Nextmune family will expedite and enhance the growth of the brands, giving pet parents and veterinary clinics continued access to proprietary topical Dermatological formulations containing MicroSilver and Ceramide III,” said Tom Bell, Founder of VetBiotek. ”Nextmune’s science-driven approach is a perfect fit for VetBiotek’s innovative solutions.”

MicroSilver BG™️ is a trademark of Bio-Gate AG.

Nextmune, renowned for its science-driven approach, operates as a global leader in specialized care and nutrition for dogs, cats, and horses, primarily centered on allergy and dermatology solutions. Their comprehensive product range, spanning diagnostics, prescription, and non-prescription offerings is available in over 70 countries, serving both veterinary professionals and pet owners worldwide.

“The addition of Vetbiotek’s unique product line to our dermatological portfolio is exciting. We will continue to provide these innovative products and look forward to improving supply and access to the MicroSilver lines,” said Megan Spencer, Country Manager for the United States. “Our dedicated sales team and industry partners will be a great support in these efforts.”

Post-acquisition, Nextmune aims to improve the production and distribution of VetBiotek's esteemed dermatological products. Veterinary clinics and distributors will seamlessly access these products through Nextmune, benefitting from enhanced inventory production and streamlined shipping processes.

To optimize the product portfolio's market presence, Nextmune will initiate a comprehensive packaging update over the next 12 months. Additionally, the company is committed to exploring advanced formulations, ensuring optimal performance and efficacy of VetBiotek's offerings.

For inquiries regarding product purchases or further information, please contact [email protected].

About Nextmune:
Nextmune is a science-driven global specialty pharma company dedicated to enhancing the health and well-being of dogs, cats, and horses. With a focus on allergy and dermatology, Nextmune's comprehensive product range spans diagnostics, prescription, and non-prescription offerings, available in over 70 countries. Driven by innovation and a passion for improving animal health, Nextmune continues to lead the way in specialized care and nutrition.

Maria Dahllöf Tullberg
Nextmune
email us here

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.